View More Recent Stories
-
Jazz Pharmaceuticals (JAZZ) PT Raised to $162 at Baird
-
Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by $1.11, Beats on Revenue; Offers FY24 Guidance
-
Jazz Pharmaceuticals (JAZZ) PT Raised to $179 at RBC Capital
-
Jazz Pharmaceuticals (JAZZ) Reports Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca and Atezolizumab Combination
-
Jazz Pharmaceuticals (JAZZ) Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO
-
Stifel Reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ)
-
Jazz Pharmaceuticals (JAZZ) Prices $850M Notes Offering
-
Jazz Pharmaceuticals (JAZZ) Announces Private $850M Exchangeable Senior Notes Offering, Concurrent Ordinary Share Repurchases
-
TD Cowen Reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ)
-
TD Cowen Reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ)
-
Jazz Pharmaceuticals (JAZZ) Cannabidiol Oral Solution Phase 3 Trial in Japan in Treatment-Resistant Epilepsies Did Not Meet Primary Efficacy Endpoint
-
Jazz Pharmaceuticals (JAZZ) PT Lowered to $166 at Piper Sandler
-
Jazz Pharmaceuticals (JAZZ) PT Lowered to $205 at Needham
-
Jazz Pharmaceuticals (JAZZ) PT Lowered to $174 at RBC Capital
-
Jazz Pharmaceuticals (JAZZ) Tops Q2 EPS by 53c
-
Jazz Pharmaceuticals (JAZZ) Appoints Laura Hamill to its Board
-
Jazz Pharmaceuticals (JAZZ) Announces Successful Completion of Term Loan Repricing and Irrevocable Election of Settlement Method for Certain Notes
-
Jazz Pharmaceuticals (JAZZ) Promotes Samantha Pearce to Chief Commercial Officer
-
Jazz Pharmaceuticals (JAZZ) PT Lowered to $113 at UBS
-
Jazz Pharmaceuticals (JAZZ) Reports Phase 2b Trial of JZP385 Did not Meet Endpoints
